Gland Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022
January 23, 2023 at 10:43 am
Share
Gland Pharma Limited reported earnings results for the third quarter and nine months ended December 31, 2022. For the third quarter, the company reported sales was INR 9,382.88 million compared to INR 10,633.25 million a year ago. Revenue was INR 9,997.97 million compared to INR 11,089.94 million a year ago. Net income was INR 2,319.49 million compared to INR 2,730.29 million a year ago. Basic earnings per share from continuing operations was INR 14.08 compared to INR 16.62 a year ago. Diluted earnings per share from continuing operations was INR 14.08 compared to INR 16.62 a year ago.
For the nine months, sales was INR 28,395.9 million compared to INR 32,976.94 million a year ago. Revenue was INR 30,411.14 million compared to INR 34,563.98 million a year ago. Net income was INR 7,023.6 million compared to INR 9,257.62 million a year ago. Basic earnings per share from continuing operations was INR 42.67 compared to INR 56.41 a year ago. Diluted earnings per share from continuing operations was INR 42.65 compared to INR 56.41 a year ago.
Gland Pharma Limited is an India-based generic injectables manufacturer. The Company specializes in sterile injectables, oncology, and ophthalmic, with a specific focus on complex injectables, NCE-1s (New Chemical Entities), First-to-File products, and 505(b)(2) filings. The Company functions primarily on a business-to-business (B2B) model and has a record in pharmaceutical research and development, manufacturing, and marketing of complex injectables. The Company offers a range of delivery systems, including liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops. It is also in the process of including new delivery systems such as pens and cartridges into its product portfolio. Its key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Its therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Gynaecological, Hormones, and others.
GLAND PHARMA LIMITED 
